Detection of Brain Metastases Using a Novel Gadolinium-Weighted MRI Sequence: A Prospective Comparison (GDW)

Region Stockholm

Status: Enrolling

Conditions: Brain Neoplasms

Treatments: Diagnostic Test: Novel Gadolinium-Weighted MRI Sequence

Study type: Observational

Funder types: Other

Identifiers

NCT07272616

K2025-9115

Details and patient eligibility

About

This study will evaluate a new type of MRI sequence designed to improve the visibility of brain metastases after gadolinium contrast injection. The purpose is to determine whether this novel "gadolinium-weighted" imaging method can detect more or smaller tumors than standard MRI techniques. Participants will undergo a routine brain MRI with contrast, followed by an additional scan using the new method. The goal is to improve diagnostic accuracy without increasing the contrast dose or scan time.

Enrollment: 100 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age 18 years or older
• Scheduled for clinical brain MRI with gadolinium contrast
• Known or suspected brain metastases
• Able to provide informed consent
• Able to lie still for the duration of the MRI examination

Exclusion criteria

• Contraindications to MRI
• Known allergy or contraindication to gadolinium-based contrast agents
• Renal impairment (eGFR < 30 mL/min/1.73m²)
• Pregnant or breastfeeding
• Inability to comply with study procedures

Trial design

100 participants in 1 patient group

Patients with Suspected or Known Brain Metastases

Description:

Participants undergoing clinically indicated brain MRI with gadolinium contrast who will receive both conventional T1-weighted imaging and the novel gadolinium-weighted MRI sequence during the same scan session. The purpose is to compare lesion detection and conspicuity between the two sequences.

Treatment:

Diagnostic Test: Novel Gadolinium-Weighted MRI Sequence